Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Genome-wide chromatin accessibility and transcriptome-wide expression changes over time in cultured primary human monocytes due to DMOG treatment

ABSTRACT: This SuperSeries is composed of the SubSeries listed below.

ORGANISM(S): Homo sapiens

PROVIDER: GSE165999 | GEO | 2022/04/13

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Genome-wide chromatin accessibility changes over time in cultured primary human monocytes due to DMOG treatment

Project description:ATAC sequencing of primary human monocytes cultured with and without hypoxia-mimetic agent DMOG (Dimethyloxalylglycine). Monocytes isolated from PBMCs of 7 healthy donors were cultured with and without DMOG for 24hrs and harvested at 0, 2, 10 or 24hrs for RNA sequencing. DMOG suppresses HIF Prolyl hydroxylase (HIF-PH) activity by acting as a small molecule competitive inhibitor. HIF-PH inhibition leads to increase in endogenous HIF protein levels and mimics aspects of hypoxia. This ATAC-seq study allows analysis of genome-wide changes to chromatin accessibility due to DMOG treatment.

2022-04-13 | GSE165997 | GEO

Transcriptome-wide expression changes over time in cultured primary human monocytes due to DMOG treatment

Project description:RNA sequencing of primary human monocytes cultured with and without hypoxia-mimetic agent DMOG (Dimethyloxalylglycine). Monocytes isolated from PBMCs of 7 healthy donors were cultured with and without DMOG for 24hrs and harvested at 0, 2, 10 or 24hrs for RNA sequencing. DMOG suppresses HIF Prolyl hydroxylase (HIF-PH) activity by acting as a small molecule competitive inhibitor. HIF-PH inhibition leads to increase in endogenous HIF protein levels and mimics aspects of hypoxia. This RNA-seq study allows analysis of transciptome-wide expression pattern changes over time due to DMOG treatment.

2022-04-13 | GSE165998 | GEO

Genome-wide chromatin accessibility changes over time in cultured primary human monocytes due to DMOG treatment

Project description:Genome-wide chromatin accessibility changes over time in cultured primary human monocytes due to DMOG treatment

| PRJNA698950 | ENA

Transcriptome-wide expression changes over time in cultured primary human monocytes due to DMOG treatment

Project description:Transcriptome-wide expression changes over time in cultured primary human monocytes due to DMOG treatment

| PRJNA698949 | ENA

Genome-wide chromatin accessibility and transcriptome-wide expression changes over time in cultured primary human monocytes due to DMOG treatment

Project description:Genome-wide chromatin accessibility and transcriptome-wide expression changes over time in cultured primary human monocytes due to DMOG treatment

| PRJNA698944 | ENA

Genome-wide chromatin accessibility changes in cultured primary human monocytes cultured at low density and high density.

Project description:ATAC sequencing of primary human monocytes cultured at low and high density. Monocytes isolated from PBMCs of 3 healthy donors were cultured at low density (1 x 10^6 cells/mL) or at high density (1 x10^7 cells/mL) for 24hrs and harvested for ATAC sequencing. Protein expression of FcgR2b is higher on monocytes in high density conditions compared to low density conditions, where expression is negligble. This study provides information on genome-wide chromatin accessibility changes that occur in high density culture in order to study associations with FcgR2b expression.

2022-04-13 | GSE166100 | GEO

Increased Accessibility to Primary Healthcare Due to Nurse Prescribing of Medicines.

Project description: Not available

| S-EPMC8751194 | biostudies-literature

Genome-wide chromatin accessibility changes in cultured primary human monocytes cultured at low density and high density.

Project description:Genome-wide chromatin accessibility changes in cultured primary human monocytes cultured at low density and high density.

| PRJNA699259 | ENA

Human gut microbiome cultured over time responsed differently to drug stimulation

Project description:In vitro gut microbiota models are often used to study drug-microbiome interaction. Similar to culturing individual microbial strains, the biomass accumulation of in vitro gut microbiota follows a logistic growth curve. Current studies on in vitro gut microbiome responses introduce drug stimulation during different growth stages, e.g. lag phase or stationary phase. However, in vitro gut microbiota in different growth phases may respond differently to a same stimuli. Therefore, in this study, we used a 96-deep well plate-based culturing model (MiPro) to culture the human gut microbiota. Metformin, as the stimulus, was added at the lag, log and stationary phases of growth. Microbiome samples were collected at different time points for optical density and metaproteomic functional analysis. Results show that in vitro gut microbiota responded differently to metformin added during different growth phases, in terms of the growth curve, alterations of taxonomic and functional compositions. The addition of drugs at log phase leads to the greatest decline of bacterial growth. Metaproteomic analysis suggested that the strength of the metformin effect on the gut microbiome functional profile was ranked as lag phase > log phase > stationary phase. Our results showed that metformin added at lag phase resulted in a significantly reduced abundance of the Clostridiales order as well as an increased abundance of the Bacteroides genus, which was different from stimulation during the rest of the growth phase. Metformin also resulted in alterations of several pathways, including energy production and conversion, lipid transport and metabolism, translation, ribosomal structure and biogenesis. Our results indicate that the timing for drug stimulation should be considered when studying drug-microbiome interactions in vitro.

2022-03-01 | PXD017390 | Pride

Genome-wide analysis of interferon regulatory factor I binding in primary human monocytes.

Project description: Not available

| S-EPMC3167955 | biostudies-literature